Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$0.43 USD
-0.01 (-2.36%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.44 +0.01 (1.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APLT 0.43 -0.01(-2.36%)
Will APLT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
Company News for Dec 2, 2024
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Other News for APLT
APLT forms Non-ADX 1,2,3,4 Bearish on September 18
Is APLT building bearish momentum? 180 Bearish Setup shows up after slipping 4.35%
Is APLT preparing to trend higher? Bullish Engulfing shows up after gaining 3.37%
APLT forms Lower Bollinger Band Walk on September 15
APLT falls 4.71% on September 12, leaving the technical picture intact